Please login to the form below

Not currently logged in
Email:
Password:

gilteritinib

This page shows the latest gilteritinib news and features for those working in and with pharma, biotech and healthcare.

Astellas, Catalyst approvals set up record year for FDA approvals

Astellas, Catalyst approvals set up record year for FDA approvals

The approvals of Astellas’ FLT3 inhibitor Xospata (gilteritinib) for acute myeloid leukaemia and Catalyst Pharmaceuticals’ Firdapse (amifampridine) for rare autoimmune disease Lambert-Eaton Myasthenic Syndrome (LEMS), already put the number for

Latest news

  • FDA fast-tracks Astellas' Rydapt rival FDA fast-tracks Astellas' Rydapt rival

    Astellas Pharma has claimed a fast-track designation in the US for its FLT3 inhibitor gilteritinib, a drug that could rival Novartis’ budding $250m-plus product Rydapt (midostaurin). ... The FDA gave the status to gilteritinib as a treatment for adults

  • Astellas extends phase III programme for Rydapt rival gilteritinib Astellas extends phase III programme for Rydapt rival gilteritinib

    Astellas has started a fourth phase III trial of acute myeloid leukaemia (AML) drug gilteritinib, a FLT3 inhibitor racing to join Novartis' recently-approved Rydapt on the market. ... Given this reality, it is exciting to study gilteritinib in patients

  • Novartis' Rydapt approval ends long AML therapy drought Novartis' Rydapt approval ends long AML therapy drought

    Meanwhile Astellas' gilteritinib - billed as a second-generation FLT3 inhibitor that avoids a resistance mechanism seen with earlier drugs - is also in late-stage testing.

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics